Florida Cancer Specialists Research To Be Presented At American Society of Clinical Oncology's Annual Meeting
Ft. Myers, FL – May 29, 2019… Florida Cancer Specialists & Research Institute (FCS) is pleased to announce that 22 research studies co-authored by FCS physicians will be published and/or presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held in Chicago, IL, May 31 – June 4, 2019. Expected to draw over 40,000 attendees, the ASCO annual meeting is the largest gathering of oncologists in the world. This year’s theme is “Caring for Every Patient, Learning from Every Patient.”
Twelve of the FCS co-authored publications are from research done through the FCS Phase 1 Drug Development Unit (DDU) in Sarasota, FL, led by Dr. Manish Patel, Director of Drug Development, and Dr. Judy Wang. Dr. Patel said, “A high percentage of the publications from the DDU trials include early and senior authorships. It is particularly gratifying that the DDU has contributed so much to the body of knowledge about new cancer treatments and research. Our strong relationship with Sarah Cannon Research Institute is pivotal to this success.”
Additional FCS physician investigators who will be published at ASCO include Drs. Jennifer Cultrera, who will also deliver a poster presentation, Gustavo Fonseca, Lucio Gordan (FCS President & Managing Physician), Elizabeth Guancial, Lowell Hart, who will also be giving an oral presentation on Saturday during the lung session, Maen Hussein, Ivor Percent, James Reeves (FCS Director of Research Operations), Daniel Spitz, Augusto Villegas, and Gail Wright.
FCS CEO Bradley Prechtl, MBA, said, “As a statewide strategic partner of Sarah Cannon Research Institute, one of the leading clinical trial organizations in the world, Florida Cancer Specialists is dedicated to refining the science and the study of malignancies and sharing knowledge and new findings that will rapidly advance and improve cancer treatments for our patients. The fact that we have so many publications accepted by ASCO is a reflection of the strong commitment to clinical research at FCS.”
FCS President and Managing Physician Dr. Lucio Gordan added, “The research program at Florida Cancer Specialists rivals that of most academic medical centers. With the drug development unit in our network, there is a dedicated program of Phase 1 Clinical Trials that puts FCS on the cutting-edge of identifying newer targeted and immunotherapies that are changing the future of cancer treatment. Over the past four years, the majority of new cancer drugs approved for use in the United States were studied in clinical trials with FCS participation, prior to FDA approval. This means that, as a community practice, we are able to bring these potentially life-saving advances to our patients in their own communities.”
About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. In the past 4 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, M.D. Anderson, and Memorial Sloan Kettering, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Founded in 1984, FCS is one of the largest medical oncology/hematology practices in the United States. With more than 230 physicians, 220 advanced practice registered nurses (APRN) and physician assistants (PA) and nearly 100 locations in our network, we are committed to providing world-class cancer care in community-based settings, close to home.
Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly-trained and dedicated physicians, clinicians and staff.
* Prior to approval
For More Information, Contact:
Florida Cancer Specialists & Research Institute
Shelly Glenn, Chief Marketing & Sales Officer
(813) 281.0088 ext. 327
Ganick Communications, Inc.